Stay updated on Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T14:22:35.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The webpage has undergone significant changes, including the removal of detailed information about a phase I trial studying the combination of ibrutinib and pembrolizumab for treating advanced melanoma, while adding new identifiers and classifications related to metastatic melanoma stages.
    Difference
    52%
    Check dated 2025-04-16T11:21:36.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 5, 2025, while a date for March 25, 2025, has been removed.
    Difference
    0.4%
    Check dated 2025-04-09T05:14:58.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T22:31:55.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T20:18:09.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The page has updated the treatment information for Pembrolizumab and Ibrutinib in relation to Stage III-IV Melanoma, with new dates and a shift in the last update timeline. Additionally, there is a notice regarding heavy traffic affecting NLM-NCBI services.
    Difference
    3%
    Check dated 2025-02-10T09:34:46.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.